MGAT5/TMEM163变异与初级胆道胆炎的ursodeoxycholic acid治疗患者的预后有关
Hanxiao Wang1, You Li1, Xiting Pu1
1Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai, 200001, China.
接近TMEM163的基因变异,特别是rs661899 T等位基因,与原发性胆道胆炎 (PBC) 患者的预后不佳有关. 这一发现表明,潜在的遗传标记可以预测对ursodeoxycholic acid (UDCA) 的治疗反应.
科学领域:
- 遗传学 遗传学 是一个
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
背景情况:
- 原发性胆道胆炎 (PBC) 是一种慢性,免疫媒介性肝病.
- 之前的研究已经确定了与PBC相关的TMEM163基因变异.
- 这项研究研究了TMEM163变体在PBC患者的预后作用.
结论:
- 在PBC患者中,rs661899 T等位基因与预后不佳和不良结果有关.
- 这种遗传标记可能有助于预测UDCA治疗反应和患者的结果.
- 结果在独立的队列中得到了验证,加强了预后意义.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
04:38Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
